The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, manufacture, ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Independent pharmacists worry that tariffs could drive companies out of business while raising prices and creating drug ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

Mounjaro and Wegovy are two of the biggest names in the world of weight-loss drugs but it's been unclear which is more effective until now. But the jabs have gone head-to-head in an effectiveness ...

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

10 Innovative Healthcare Stocks to Watch in 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other innovative healthcare stocks to ...